Of course all this got started as a result of the Avandia bru-ha-ha. I‘ve ranted about this macrovascular issue here and elsewhere. Here’s an expert who seems to agree, commenting in a recent issue of DOC News:
But as a medical community, do we want to prove that our agents to treat type 2 diabetes improve heart attack and stroke risk before approval?
I think not.